Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/STROKEAHA.109.562181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis.
Front Med (Lausanne)
January 2025
Department Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Objective: This study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC).
Methods: PubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched to identify related randomized controlled trials (RCTs).
Results: Seven RCTs involving 4,363 participants were included.
Safety and Efficacy of Baricitinib, Upadacitinib, and Sarilumab Implementation in Moderately-to-Severely Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Current Evidence.
Cureus
December 2024
Department of Anesthesiology and Intensive Care, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, GRC.
This study aims to assess the efficacy and safety of newly approved Janus kinase (JAK) and interleukin-6 (IL-6) inhibitors in patients with moderately-to-severely active rheumatoid arthritis (RA) with inadequate response to or intolerance of conventional disease-modifying antirheumatic drugs. We conducted a systematic review and meta-analysis of all placebo-controlled randomized trials assessing baricitinib, sarilumab, and upadacitinib treatment in RA, published in PubMed and CENTRAL (Cochrane Central Register of Controlled Trials) databases up to October 2023. The study outcomes involved the American College of Rheumatology (ACR) 20%, 50%, and 70% responses, Health Assessment Questionnaire-Disability Index (HAQ-DI), Disease Activity Score in 28 joints (DAS28), serious adverse events, and adverse events leading to drug discontinuation.
View Article and Find Full Text PDFAssessing the readability, quality and reliability of responses produced by ChatGPT, Gemini, and Perplexity regarding most frequently asked keywords about low back pain.
PeerJ
January 2025
Anesthesiology and Reanimation, Central Clinical Hospital, Baku, Azerbaijan.
Background: Patients who are informed about the causes, pathophysiology, treatment and prevention of a disease are better able to participate in treatment procedures in the event of illness. Artificial intelligence (AI), which has gained popularity in recent years, is defined as the study of algorithms that provide machines with the ability to reason and perform cognitive functions, including object and word recognition, problem solving and decision making. This study aimed to examine the readability, reliability and quality of responses to frequently asked keywords about low back pain (LBP) given by three different AI-based chatbots (ChatGPT, Perplexity and Gemini), which are popular applications in online information presentation today.
View Article and Find Full Text PDFUtilizing whole genome sequencing to characterize central line-associated bloodstream infections due to .
Infect Control Hosp Epidemiol
January 2025
Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Whole genome sequencing (WGS) and clinical review were used to characterize 14 cases of central line-associated bloodstream infection (CLABSI) due to . WGS, which demonstrated disparate strains, suggested that 42.9% of CLABSI cases were due to contamination, while clinical review suggested that 57.
View Article and Find Full Text PDFThe Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostate
January 2025
Department of Urology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
Background: Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting. Actinium 225 (Ac) prostate-specific membrane antigen (PSMA) radioligand therapy has emerged as a promising option and has been utilized for the last decade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!